Precision Medicine and Targeted Therapies in Neuroblastoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".
Deadline for manuscript submissions: 30 July 2026 | Viewed by 699
Special Issue Editor
Special Issue Information
Dear Colleagues,
Neuroblastoma, a childhood embryonal tumor arising from sympathoadrenal precursors, remains a significant clinical challenge. Patients with high-risk disease are treated with toxic combinations of chemotherapy, radiation therapy, and anti-GD2 immunotherapy, and yet 5-year progression free survival for these patients remains less than 65%, and survivors are left with significant morbidities. Preclinical studies have identified the role of additional oncogenic pathways in disease resistance, including immortalization through telomere maintenance mechanisms, alternative metabolomics, and the activation of orthogonal oncogenic pathways, among others. Novel approaches are needed to attack these critical nodes of neuroblastoma viability, both through the development of new therapeutics and through the repurposing of available agents. Innovative study designs will also be necessary, making use of integrative diagnostics and theranostics to personalize therapy, and also using combination therapies for synergistic efficacy and reduced toxicity. We invite submissions on basic laboratory, preclinical, and clinical research that can highlight these paths to improved outcomes for children with neuroblastoma.
Dr. Nilay Shah
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pediatric oncology
- solid tumors
- targeted therapies
- biomarkers of response
- novel combination therapies
- tumor microenvironment
- integrative diagnostics
- theranostics
- telomere maintenance mechanisms
- neuroblastoma
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
